BeyondSpring
BeyondSpring Pharmaceuticals is a biopharmaceutical company focused on the development of innovative cancer therapies with a business model integrating US and Chinese clinical resources.
The company is advancing its lead asset, an immuno-oncology agent plinabulin, in a global Phase III trial for the reduction of docetaxel-induced neutropenia and another Phase III study as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer.
Plinabulin is also entering Phase I/II trials to investigate its therapeutic potential in immuno-oncology.
Latest BeyondSpring News & Features
2 December 2021
14 November 2020
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze